140 related articles for article (PubMed ID: 35300217)
1.
Xu Y; Li J; He B; Feng T; Liang L; Huang X
Front Vet Sci; 2022; 9():815198. PubMed ID: 35300217
[TBL] [Abstract][Full Text] [Related]
2. The Bioavailability and Pharmacokinetics of Silymarin SMEDDS Formulation Study in Healthy Thai Volunteers.
Sornsuvit C; Hongwiset D; Yotsawimonwat S; Toonkum M; Thongsawat S; Taesotikul W
Evid Based Complement Alternat Med; 2018; 2018():1507834. PubMed ID: 30108644
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the in-vitro dissolution and in-vivo oral bioavailability of silymarin from liquid-filled hard gelatin capsules of semisolid dispersion using Gelucire 44/14 as a carrier.
Hussein A; El-Menshawe S; Afouna M
Pharmazie; 2012 Mar; 67(3):209-14. PubMed ID: 22530301
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of a silybin-phosphatidylcholine complex in dogs.
Filburn CR; Kettenacker R; Griffin DW
J Vet Pharmacol Ther; 2007 Apr; 30(2):132-8. PubMed ID: 17348898
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.
Sawicki E; Verheijen RB; Huitema AD; van Tellingen O; Schellens JH; Nuijen B; Beijnen JH; Steeghs N
Drug Deliv Transl Res; 2017 Feb; 7(1):125-131. PubMed ID: 27864786
[TBL] [Abstract][Full Text] [Related]
6. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats.
Yanyu X; Yunmei S; Zhipeng C; Qineng P
Int J Pharm; 2006 Jan; 307(1):77-82. PubMed ID: 16300915
[TBL] [Abstract][Full Text] [Related]
7. Silymarin-solid dispersions: characterization and influence of preparation methods on dissolution.
Sonali D; Tejal S; Vaishali T; Tejal G
Acta Pharm; 2010 Dec; 60(4):427-43. PubMed ID: 21169135
[TBL] [Abstract][Full Text] [Related]
8. A novel solid dispersion system for natural product-loaded medicine: silymarin-loaded solid dispersion with enhanced oral bioavailability and hepatoprotective activity.
Hwang du H; Kim YI; Cho KH; Poudel BK; Choi JY; Kim DW; Shin YJ; Bae ON; Yousaf AM; Yong CS; Kim JO; Choi HG
J Microencapsul; 2014; 31(7):619-26. PubMed ID: 24766208
[TBL] [Abstract][Full Text] [Related]
9. Preparation and Characterization of Silymarin Synchronized and Sustained Release Dropping Pill.
Liu ZH; Li XJ; Huang AW; Zhang J; Song HT
Curr Drug Deliv; 2017; 14(5):650-657. PubMed ID: 28201965
[TBL] [Abstract][Full Text] [Related]
10. Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen.
Daravath B; Tadikonda RR; Vemula SK
Drug Dev Ind Pharm; 2015; 41(8):1254-62. PubMed ID: 25039470
[TBL] [Abstract][Full Text] [Related]
11. Comparative bioavailability of silibinin in healthy male volunteers.
Kim YC; Kim EJ; Lee ED; Kim JH; Jang SW; Kim YG; Kwon JW; Kim WB; Lee MG
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):593-6. PubMed ID: 14692709
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of extended-release ivermectin microspheres after oral administration to healthy pigs.
Xu Y; Zhang S; Qiu Y; Yu Y; Zhang Y; Huang X
J Vet Pharmacol Ther; 2020 Sep; 43(5):485-490. PubMed ID: 32304335
[TBL] [Abstract][Full Text] [Related]
13. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs.
Yan-yu X; Yun-mei S; Zhi-peng C; Qi-neng P
Int J Pharm; 2006 Aug; 319(1-2):162-8. PubMed ID: 16687221
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of silipide and silymarin in rats.
Morazzoni P; Montalbetti A; Malandrino S; Pifferi G
Eur J Drug Metab Pharmacokinet; 1993; 18(3):289-97. PubMed ID: 8149949
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Bioavailability and Efficacy of Silymarin Solid Dispersion in Rats with Acetaminophen-Induced Hepatotoxicity.
Song IS; Nam SJ; Jeon JH; Park SJ; Choi MK
Pharmaceutics; 2021 Apr; 13(5):. PubMed ID: 33925040
[TBL] [Abstract][Full Text] [Related]
16. Superior silybin bioavailability of silybin-phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers.
Méndez-Sánchez N; Dibildox-Martinez M; Sosa-Noguera J; Sánchez-Medal R; Flores-Murrieta FJ
BMC Pharmacol Toxicol; 2019 Jan; 20(1):5. PubMed ID: 30635055
[TBL] [Abstract][Full Text] [Related]
17. [Relativities between lattice changes and the function of dissolution improvement of poorly soluble drug silymarin based upon PEG 6,000 solid dispersion system].
Li FQ; Hu JH; Wang H; Zhu QG; Sun HJ; Cai Z
Yao Xue Xue Bao; 2002 Apr; 37(4):294-8. PubMed ID: 12579827
[TBL] [Abstract][Full Text] [Related]
18. Assessing the potential of solid dispersions to improve dissolution rate and bioavailability of valsartan: In vitro-in silico approach.
Medarević D; Cvijić S; Dobričić V; Mitrić M; Djuriš J; Ibrić S
Eur J Pharm Sci; 2018 Nov; 124():188-198. PubMed ID: 30144529
[TBL] [Abstract][Full Text] [Related]
19. Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs.
Yang B; Wu C; Ji B; Wu M; He Z; Shang L; Sun J
Asian J Pharm Sci; 2017 Jan; 12(1):98-104. PubMed ID: 32104318
[TBL] [Abstract][Full Text] [Related]
20. Predicting in vivo performance of fenofibrate amorphous solid dispersions using in vitro non-sink dissolution and dissolution permeation setup.
Lentz KA; Plum J; Steffansen B; Arvidsson PO; Omkvist DH; Pedersen AJ; Sennbro CJ; Pedersen GP; Jacobsen J
Int J Pharm; 2021 Dec; 610():121174. PubMed ID: 34655705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
